Dimensional Fund Advisors LP Purchases 119,927 Shares of Cencora, Inc. (NYSE:COR)

Dimensional Fund Advisors LP boosted its position in shares of Cencora, Inc. (NYSE:COR) by 10.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,262,882 shares of the company’s stock after purchasing an additional 119,927 shares during the period. Dimensional Fund Advisors LP owned about 0.63% of Cencora worth $284,544,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Black Creek Investment Management Inc. grew its stake in shares of Cencora by 7.8% during the second quarter. Black Creek Investment Management Inc. now owns 24,873 shares of the company’s stock valued at $5,604,000 after buying an additional 1,809 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Cencora by 4.2% in the second quarter. Envestnet Asset Management Inc. now owns 560,450 shares of the company’s stock worth $126,269,000 after purchasing an additional 22,735 shares during the period. Oppenheimer Asset Management Inc. lifted its position in shares of Cencora by 2.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 28,452 shares of the company’s stock worth $6,410,000 after purchasing an additional 616 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Cencora by 6.4% during the second quarter. Parallel Advisors LLC now owns 4,961 shares of the company’s stock valued at $1,118,000 after purchasing an additional 299 shares during the period. Finally, Dai ichi Life Insurance Company Ltd grew its holdings in shares of Cencora by 8.1% in the second quarter. Dai ichi Life Insurance Company Ltd now owns 80,665 shares of the company’s stock worth $18,174,000 after purchasing an additional 6,015 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock worth $1,070,392,799 in the last ninety days. 15.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on COR. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners reissued an “outperform” rating and set a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th. Finally, Robert W. Baird decreased their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $258.13.

Cencora Price Performance

Shares of COR stock opened at $234.53 on Wednesday. The company has a market cap of $46.78 billion, a P/E ratio of 25.66, a PEG ratio of 1.55 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock’s 50-day moving average is $234.52 and its 200 day moving average is $233.26. Cencora, Inc. has a 1-year low of $177.00 and a 1-year high of $247.66.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. During the same period last year, the business earned $2.92 EPS. The company’s revenue was up 10.8% compared to the same quarter last year. Research analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s payout ratio is 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.